Ashley Yeo
Executive Editor, MTI; Medtech Editor, In Vivo
Ashley has reported on health care market issues with Citeline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).
Latest From Ashley Yeo
Medtechs Are Fully Engaged In Climate Change: ‘They Have No Choice’
The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.
Trunzo: ’We’ve Come A Long Way To Get To Regulatory Reliance’
Medical device regulatory reliance and recognition of third-party regulators’ approvals have been making news in the UK, but in certain other markets the practice is well established. International regulatory experts explained their experiences at the MedTech Forum 2024.
China Market For Medtech: Opportunity Or Headache?
Medtech companies have typically seen a “mixed picture of growth” in China in the past year or two, but it is a market that requires ongoing commitment, a panel of experts argued at the MedTech Forum 2024.
UK Government Accentuates Role Of Medtech As It Orders Review Of NHS
One week after winning the UK general election on 4 July, the Labour Party ordered a review of the National Health Service, to be published in September.
Lucid Diagnostics Seeks Clear Path To US Reimbursement For Esophageal Precancer Test
Lishan Aklog, CEO of New York-based Lucid Diagnostics, has a long-term vision to provide the paradigm of prevention-to-treatment care for esophageal cancer. In the short term, the company anticipates a favorable outcome from an upcoming pivotal Medicare assessment of its early screening technology.
Lucid Diagnostics Seeks Clear Path To US Reimbursement For Esophageal Precancer Test
Lishan Aklog, CEO of New York-based Lucid Diagnostics, has a long-term vision to provide the paradigm of prevention-to-treatment care for esophageal cancer. In the short term, the company anticipates a favorable outcome from an upcoming pivotal Medicare assessment of its early screening technology.